antibody

Rabbit anti-human kininogen 1 polyclonal Antibody

MBS710883

0.05 mL

375 USD

polyclonal

rabbit

nonconjugated

western blot, ELISA, immunohistochemistry, enzyme immunoassay

Antibody

Rabbit anti-human kininogen 1 polyclonal Antibody

kininogen 1

kininogen 1; KNG1; BDK; KNG

kininogen-1 isoform 1; Kininogen-1; kininogen-1; HMWK; bradykinin; fitzgerald factor; high molecular weight kininogen; alpha-2-thiol proteinase inhibitor; williams-Fitzgerald-Flaujeac factor; kininogen 1; Alpha-2-thiol proteinase inhibitor; Fitzgerald factor; High molecular weight kininogen; HMWK; Williams-Fitzgerald-Flaujeac factorCleaved into the following 6 chains:Kininogen-1 heavy chain; T-kininAlternative name(s):Ile-Ser-Bradykinin

KNG1; KNG1; BK; BDK; KNG; BDK; KNG; HMWK

KNG1_HUMAN

Polyclonal

IgG

Rabbit

Human; Other species are not tested. Please decide the specificity by homology.

644

Antigen Affinity Purified

Liquid

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

Tested applications:. ELISA: Use at an assay dependent dilution. WB: 1:200-1:2000 . IHC: 1:20-1:200 . IF: 1:10-1:100 (Recommender dilutions) . Positive WB detected in: HeLa cells, A2780 cells, COLO 320 cells, MCF7 cells . Positive IHC detected in: Human endometrial cancer tissue. Positive IF detected in: HepG2 cells

Immunogen: Human KNG1. Conjugate : Non-conjugated

Storage Buffer: PBS with 0.1% sodium azide and 50% glycerol pH 7.3.

(1)Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikreinand factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin-and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

156231037

NP_001095886.1

NM_001102416.2

43,822 Da

ACE Inhibitor Pathway (198763); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); G Alpha (i) Signalling Events Pathway (119550); G Alpha (q) Signalling Events Pathway (106043); GPCR Downstream Signaling Pathway (119548); GPCR Ligand Binding Pathway (161020)

This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Oct 2009]

KNG1: (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW- kininogen is in contrast to HMW-kininogen not involved in blood clotting. Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency). HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Secreted, signal peptide; Inhibitor; Contractile; Cell adhesion; Motility/polarity/chemotaxis; Secreted. Chromosomal Location of Human Ortholog: 3q27. Cellular Component: extracellular space; extracellular region; plasma membrane. Molecular Function: heparin binding; protein binding; zinc ion binding; cysteine protease inhibitor activity; receptor binding. Biological Process: negative regulation of proteolysis; platelet activation; elevation of cytosolic calcium ion concentration; smooth muscle contraction; platelet degranulation; positive regulation of apoptosis; negative regulation of blood coagulation; negative regulation of cell adhesion; inflammatory response; blood coagulation; vasodilation; blood coagulation, intrinsic pathway. Disease: High Molecular Weight Kininogen Deficiency

0.05 mL

375 USD

0.15 mL

715